The investigation by Levi & Korsinsky into AstraZeneca for potential securities law violations, coupled with the Chinese fraud probe, is likely to negatively impact investor sentiment and the stock price in the short term. Legal issues and regulatory scrutiny often lead to uncertainty and potential financial penalties, which can weigh on stock performance.